Latest Conference Coverage


Patients Receiving Efgartigimod Respond to COVID-19 Vaccination With IgG Antibodies

September 25th 2022

In an investigation on the effect of treatment with efgartigimod on humoral immune responses to COVID-19 vaccination, the immunization resulted in antigen-specific IgG responses in most patients.


Understanding New Guidelines to Improve Management of Painful Diabetic Neuropathies

September 25th 2022

Brian Callaghan, MD, MS, associate professor at the University of Michigan, discussed his presentation at AANEM 2022 on changing the treatment paradigm for painful diabetic neuropathies.


NeurologyLive® Brain Games: September 25, 2022

September 25th 2022

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the American Association of Neuromuscular & Electrodiagnostic Medicine.


Repetitive Nerve Stimulation Exhibits Positive Association with Inpatient Diagnosis of Myasthenia Gravis

September 24th 2022

Findings from retrospective study show that repetitive nerve stimulation is a highly sensitive and specific test for the diagnosis of myasthenia gravis in an inpatient setting, with its results being more rapidly available in comparison with antibody testing.


Unique Composition of CNM-Au8 to Treat MS and ALS: Michael Hotchkin

September 24th 2022

The chief development officer at Clene Nanomedicine provided insight on why CNM-Au8, an investigational agent in development, has shown positive results across both multiple sclerosis and ALS. [WATCH TIME: 2 minutes]


Substantial Economic Burden Is Frequent in Myasthenia Gravis, Primarily Driven by Direct Costs

September 24th 2022

Among a surveyed cohort of patients with myasthenia gravis, 75% reported that their work was impacted, and 27% of respondents claimed they lost wages as a result of MG.


Eplontersin Treatment Results in Reduction in Serum Transthyretin in Amyloidosis

September 23rd 2022

Eplontersen treatment resulted in a significant reduction in transthyretin, neuropathy impairment, and improvement in quality of life in the phase 3 NEURO-TTRansform study of patients with hereditary transthyretin amyloidosis.


Rozanolixizumab Continues to Show Efficacy, High Responder Rates in Myasthenia Gravis

September 23rd 2022

Minimal symptom expression, demonstrated by scores of 0 to 1 on MG-ADL, was observed in more than 25% of both rozanolixizumab groups compared with 3.0% of those on placebo.


CNM-Au8’s Impact on Survival, Energetic Dysfunction in ALS: Michael Hotchkin

September 23rd 2022

The chief development officer at Clene Nanomedicine provided insight on the mechanistic function of CNM-Au8 and how it improves survival in patients with ALS. [WATCH TIME: 3 minutes]


Pooled Clinical Trial Data Suggests Antidrug Antibody Testing for Alglucosidase Alfa-Exposed Patients With Pompe Disease

September 23rd 2022

Investigators concluded that those receiving avalglucosidase alfa should be tested for antidrug antibodies by physicians who treat Pompe disease and monitor antidrug antibody, according to a recent Sanofi investigation.


ADAPT/ADAPT+ Study Show Improvements in Myasthenia Gravis Efficacy Scales With Efgartigimod

September 22nd 2022

ADAPT+ study data on antiacetylcholine receptor antibody-negative patients with generalized myasthenia gravis found improvements in cycle baseline and efficacy with Efgartigimod.


Changing the Treatment of Diabetic and Inflammatory Neuropathies: Brian Callaghan, MD, MS

September 22nd 2022

The associate professor at the University of Michigan provided insight on new guidelines to treat painful diabetic neuropathy. [WATCH TIME: 2 minutes]


Potential Temporal Association Found Between Guillain-Barré Syndrome and COVID-19 Vaccination in Pediatrics

September 22nd 2022

From the pre-COVID period to 6 weeks after vaccination, the reporting rate of GBS was significantly different, regardless of whether Brighton criteria was applied to the analysis. The authors noted that passive surveillance limitations warrant further analysis.


CNM-Au8 Displays Evidence of Survival Benefit in Amyotrophic Lateral Sclerosis

September 22nd 2022

Results from phase 2 RESCUE-ALS trial show that treatment with CNM-Au8 in ALS demonstrated improvement in survival compared to the estimated median survival rate.


Design of Phase 3 URSA Study of Tolebrutinib in Myasthenia Gravis Detailed

September 21st 2022

The phase 3 study, paused at US sites by the FDA, seeks to enroll 154 individuals with generalized myasthenia gravis, both seropositive and seronegative.


High Proportion of Zilucoplan Responders Identified in Secondary Analysis of RAISE Trial

September 21st 2022

After 12 weeks of treatment with zilucoplan 0.3 mg/kg, almost three-fourths of patients demonstrated at least a 3-point reduction in Myasthenia Gravis Activities of Daily Living scores.


Cipaglucosidase Alfa/Miglustat Shows Beneficial Treatment Effects for Patients With Late-onset Pompe Disease

September 21st 2022

Most ambulatory patients had improved pulmonary functions and biomarker outcomes with cipaglucosidase alfa/miglustat that were sustained through a less than 36-month follow-up period.


Migraine Linked to Increased Risk of Parkinson Disease in the Middle-aged and Older Population

September 20th 2022

A study presented at the MDS Congress 2022 found an association between migraine and the incidence of Parkinson disease in the middle-aged and older population.


IncobotulinumtoxinA Supported for the Treatment of Neurological Disorders in Adults

September 19th 2022

Results from a pooled analysis extend and support the safety and the tolerability of the use of incobotulinumtoxinA for the treatment of adults with neurological disorders.


Several Genetic Loci Show Increased Risk of Mortality, Cognitive Impairment in Parkinson Disease

September 19th 2022

One of the identified loci related to clinical progression in Parkinson disease expresses ADORA2A in the cerebellum, which encodes the adenosine A2A receptor, a promising target for therapeutics in PD.


Selective Adenosine A2A Antagonist KW-6356 Demonstrates Efficacy, Safety as Adjunct to Levodopa in Parkinson Disease

September 18th 2022

The Parkinson disease agent showed a safe and tolerable profile, with significantly greater improvements in MDS-UPDRS-III scores and OFF time per day.


Remote Yoga Program Feasible and Benefits Individuals with Functional Neurological Disorder

September 17th 2022

Danielle Kipnis, MA, of Columbia University, discussed key components of a yoga program for individuals with functional neurological disorder and from the evaluation, found it feasibility as an intervention.


Multiple-Source Constant-Current DBS Improves Quality of Life in Parkinson Disease, Real-World Analysis Suggests

September 16th 2022

Over a 2-year period, patients demonstrated improvements in Parkinson’s Disease Questionnaire scores, along with a 35% improvement in MDS-UPDRS-III scores.


NeuroVoices: Lynn Bekris, PhD, on Future Research for sTREM2, GFAP, and Immunotherapies in Alzheimer Disease

September 14th 2022

The molecular biologist at the Cleveland Clinic Lerner Research Institute discussed the unanswered questions regarding biomarkers sTREM2 and GFAP, and the role they play in Alzheimer pathology.


NeuroVoices: Lynn Bekris, PhD, on sTREM2 and GFAP to Differentiate Cognitive Status, Trajectory

September 7th 2022

The molecular biologist at the Cleveland Clinic Lerner Research Institute provided commentary on how certain activity markers may help understand immune response differences in Alzheimer disease and related dementias.

© 2023 MJH Life Sciences

All rights reserved.